Search

Your search keyword '"Toyama, Takanori"' showing total 16 results
Start Over Author "Toyama, Takanori" Publication Year Range Last 10 years
16 results on '"Toyama, Takanori"'

1. Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan

Author

Usuki, Kensuke, Kameda, Takuro, Kawano, Noriaki, Ito, Tomoki, Hashimoto, Yoshinori, Shide, Kotaro, Kawano, Hiroshi, Sekine, Masaaki, Toyama, Takanori, Iizuka, Hiromitsu, Sato, Seiichi, Takeuchi, Masanori, Ishizaki, Junzo, Maeda, Kouichi, Nakai, Michikazu, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya

Published
2024
Full Text
View/download PDF

2. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia

Author

Kamiunten, Ayako, Shide, Kotaro, Kameda, Takuro, Ito, Masafumi, Sekine, Masaaki, Kubuki, Yoko, Hidaka, Tomonori, Akizuki, Keiichi, Tahira, Yuki, Toyama, Takanori, Kawano, Noriaki, Marutsuka, Kousuke, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Shimoda, Haruko, Yamashita, Kiyoshi, Matsuoka, Hitoshi, and Shimoda, Kazuya

Published
2018
Full Text
View/download PDF

3. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan

Author

Kamiunten, Ayako, Shide, Kotaro, Kameda, Takuro, Sekine, Masaaki, Kubuki, Yoko, Ito, Masafumi, Toyama, Takanori, Kawano, Noriaki, Marutsuka, Kousuke, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Matsuoka, Hitoshi, and Shimoda, Kazuya

Published
2018
Full Text
View/download PDF

4. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma

Author

Kameda, Takuro, primary, Kataoka, Keisuke, additional, Kamiunten, Ayako, additional, Hidaka, Michihiro, additional, Miyoshi, Hiroaki, additional, Nakano, Nobuaki, additional, Nosaka, Kisato, additional, Yoshimitsu, Makoto, additional, Yasunaga, Jun-ichirou, additional, Kogure, Yasunori, additional, Shide, Kotaro, additional, Miyahara, Masaharu, additional, Sakamoto, Takashi, additional, Akizuki, Keiichi, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Koya, Junji, additional, Kawano, Noriaki, additional, Yamashita, Kiyoshi, additional, Kawano, Hiroshi, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Marutsuka, Kosuke, additional, Imaizumi, Yoshitaka, additional, Kato, Koji, additional, Sugio, Takeshi, additional, Tokunaga, Masahito, additional, Tashiro, Yukie, additional, Takaori-Kondo, Akifumi, additional, Miyazaki, Yasushi, additional, Akashi, Koichi, additional, Ishitsuka, Kenji, additional, Matsuoka, Masao, additional, Ohshima, Koichi, additional, Watanabe, Toshiki, additional, Kitanaka, Akira, additional, Utsunomiya, Atae, additional, Ogawa, Seishi, additional, and Shimoda, Kazuya, additional

Published
2023
Full Text
View/download PDF

6. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

Author

Kameda, Takuro, primary, Shide, Kotaro, additional, Tahira, Yuki, additional, Sekine, Masaaki, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Takeuchi, Masanori, additional, Akizuki, Keiichi, additional, Kamiunten, Ayako, additional, Shimoda, Haruko, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Yamashita, Kiyoshi, additional, Kawano, Noriaki, additional, Kawano, Hiroshi, additional, Hidaka, Tomonori, additional, Yamaguchi, Hideki, additional, Kubuki, Yoko, additional, Kitanaka, Akira, additional, Matsuoka, Hitoshi, additional, and Shimoda, Kazuya, additional

Published
2022
Full Text
View/download PDF

8. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

Author

Akizuki, Keiichi, primary, Matsuoka, Hitoshi, additional, Toyama, Takanori, additional, Kamiunten, Ayako, additional, Sekine, Masaaki, additional, Shide, Kotaro, additional, Kameda, Takuro, additional, Kawano, Noriaki, additional, Maeda, Kouichi, additional, Takeuchi, Masanori, additional, Kawano, Hiroshi, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Tahira, Yuki, additional, Shimoda, Haruko, additional, Hidaka, Tomonori, additional, Yamashita, Kiyoshi, additional, Kubuki, Yoko, additional, and Shimoda, Kazuya, additional

Published
2020
Full Text
View/download PDF

9. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma

Author

Sekine, Masaaki, primary, Kameda, Takuro, additional, Shide, Kotaro, additional, Maeda, Kouichi, additional, Toyama, Takanori, additional, Kawano, Noriaki, additional, Takeuchi, Masanori, additional, Kawano, Hiroshi, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Kukita, Toshimasa, additional, Kamiunten, Ayako, additional, Akizuki, Keiichi, additional, Tahira, Yuki, additional, Shimoda, Haruko, additional, Hidaka, Tomonori, additional, Yamashita, Kiyoshi, additional, Matsuoka, Hitoshi, additional, Kitanaka, Akira, additional, Kubuki, Yoko, additional, and Shimoda, Kazuya, additional

Published
2020
Full Text
View/download PDF

12. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma.

Author

Sekine, Masaaki, Kameda, Takuro, Shide, Kotaro, Maeda, Kouichi, Toyama, Takanori, Kawano, Noriaki, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Kukita, Toshimasa, Kamiunten, Ayako, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Matsuoka, Hitoshi, Kitanaka, Akira, and Kubuki, Yoko

Subjects
ADULT T-cell leukemia, CANCER chemotherapy, T-cell lymphoma, LYMPHOMAS, PROGNOSIS
Abstract

Objective and Method: Adult T‐cell leukemia/lymphoma (ATL) is an aggressive peripheral T‐cell lymphoma with poor prognosis. We retrospectively reviewed the medical records of 312 patients with aggressive ATL and analyzed the effect of chemotherapy dose intensity on prognosis in clinical practice. Result: As first‐line therapy, 62 patients underwent best supportive care (BSC) or single‐agent chemotherapy, and 235 underwent intensive chemotherapy. The median survival time (MST) was 0.58 years in the 312 total patients, and 0.13 years and 0.75 years in the BSC/single‐agent chemotherapy group and intensive chemotherapy group, respectively. The median average relative dose intensity (ARDI) of patients who received intensive chemotherapy was 60%. We divided patients into 3 groups according to ARDI. Those in the top tertile of ARDI (ARDI ≥ 75%, n = 82) had better overall survival compared with those in the intermediate tertile (45% ≤ ARDI < 75%, n = 79) (P <.0001), with MSTs of 4.69 and 0.75 years, respectively. The occurrence of organ dysfunction and infectious complications was comparable between the two ARDI groups. Conclusion: Higher ARDI improves prognosis in patients with aggressive ATL in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice

Author

Sekine, Masaaki, primary, Kubuki, Yoko, additional, Kameda, Takuro, additional, Takeuchi, Masanori, additional, Toyama, Takanori, additional, Kawano, Noriaki, additional, Maeda, Kouichi, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Kawano, Hiroshi, additional, Kamiunten, Ayako, additional, Akizuki, Keiichi, additional, Tahira, Yuki, additional, Shimoda, Haruko, additional, Shide, Kotaro, additional, Hidaka, Tomonori, additional, Kitanaka, Akira, additional, Yamashita, Kiyoshi, additional, Matsuoka, Hitoshi, additional, and Shimoda, Kazuya, additional

Published
2017
Full Text
View/download PDF

14. Mogamulizumab for ATLL in Clinical Practice

Author

Sekine, Masaaki, primary, Takeuchi, Masaki, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Sato, Seiichi, additional, Yamashita, Kiyoshi, additional, Ishizaki, Junzo, additional, Keiichi, Akizuki, additional, Kamiunten, Ayako, additional, Kameda, Takuro, additional, Shide, Kotaro, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Kitanaka, Akira, additional, and Shimoda, Kazuya, additional

Published
2016
Full Text
View/download PDF

15. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.

Author

Akizuki, Keiichi, Matsuoka, Hitoshi, Toyama, Takanori, Kamiunten, Ayako, Sekine, Masaaki, Shide, Kotaro, Kameda, Takuro, Kawano, Noriaki, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya

Subjects
MULTIPLE myeloma, PROGNOSIS, STEM cell transplantation, DIAGNOSIS, MULTIVARIATE analysis, PLASMACYTOMA
Abstract

The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

16. [A transient lymphocytosis after administration of tirabrutinib for leukemic Waldenström macroglobulinemia].

Author

Toyama T

Subjects
Female, Humans, Aged, 80 and over, Mutation, Leukocytosis, Myeloid Differentiation Factor 88 genetics, Immunoglobulin M, Waldenstrom Macroglobulinemia genetics, Lymphocytosis chemically induced, Lymphoma, B-Cell
Abstract

An 85-year-old woman was admitted to our hospital because of leukocytosis. Abnormal lymphocytic leukocytosis, including few plasmacytes, anemia, and thrombocytopenia, were observed. A diagnosis of primary macroglobulinemia was made based on immunoglobulin M-kappa monoclonal gammopathy, FACS of abnormal lymphocytes, and confirmed MYD88 L265P somatic mutation. Abnormal lymphocytes were markedly increased temporarily after the administration of tirabrutinib. However, the patient continued treatment after abdominal computed tomography showed that splenomegaly and lymphadenopathy had improved, and the patient recovered from leukocytosis. There are no reports that leukocytosis is a side effect of tirabrutinib; therefore, this case can be considered unique.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results